# Zenitar

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zenitar

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Website: www.zenitar.com.cn/
- Total disclosed funding: $103M
- Latest round: Series C (Jan 12, 2026)
- Investors on record: 16

## About

Based in Chengdu, China and established in 2019, Chengdu Zenitar Biomedical Technology Co., Ltd., trading as Zenitar is a biopharmaceutical research and development company dedicated to the drug research and development. It has acquired High-Tech Enterprise Certificate. It has 26 independent intellectual property rights and 24 patents. The chairman and CSO of the company, Lijuan Chen graduated from University of Wales Swansea and has worked in Guangdong Zhongsheng Pharmaceutical Co., Ltd. In January 2026, Zenitar raised CNY 600 million in Series C funding co-led by returning investor Qiming Venture Partners and new investor True Light Capital, with participation from returning investors 5Y Capital, Sichuan Development Industry Led Equity Investment Fund Management, BIO-TOWN Capital, Huajin Lingchuang Fund Management and new investors NRL Capital, Tencent Investment, Lanchi Ventures, Xiamen C&D Group, Shanghai STVC Group.
The company R&D of new drug that includes tumors, autoimmune diseases, and cytokine storm caused by new coronavirus pneumonia. The company's disease research areas include B-cell related tumors, multiple myeloma, polycythemia vera, essential thrombocythemia. 
The company generates revenue by developing structural biology and artificial intelligence-driven medicines.

## Funding rounds

- Series C, Jan 12, 2026, $86M — Qiming Venture Partners, 5Y Capital, Shanghai STVC Group, Xiamen C&D Group, Lanchi Ventures, Sichuan Development Industry Led Equity Investment Fund Management, Huajin Lingchuang Fund Management, NRL Capital, True Light Capital, BIO-TOWN Capital, Tencent Investment
- Series B, Nov 9, 2025 — BIO-TOWN Capital
- Series B, Nov 24, 2023 — Chengdu Science and Technology Venture Capital Group, Huajin Lingchuang Fund Management, Sichuan Venture Capital, Orinno Capital, ChongQing ShengZhong Investment Mangement Co ,Ltd
- Series A, Dec 8, 2021, $17M — New Value Capital, Sichuan Development Industry Led Equity Investment Fund Management, Sichuan Venture Capital, BIO-TOWN Capital

## Investors

- New Value Capital — Series A
- Sichuan Development Industry Led Equity Investment Fund Management — Series A, Series C
- Sichuan Venture Capital (https://capitalatlas.ai/funds/sichuan-venture-capital) — Series A, Series B
- BIO-TOWN Capital (https://capitalatlas.ai/funds/bio-town-capital) — Series A, Series B, Series C
- Chengdu Science and Technology Venture Capital Group (https://capitalatlas.ai/funds/chengdu-science-and-technology-venture-capital-group) — Series B
- Huajin Lingchuang Fund Management (https://capitalatlas.ai/funds/huajin-lingchuang-fund-management) — Series B, Series C
- Orinno Capital (https://capitalatlas.ai/funds/orinno-capital) — Series B
- ChongQing ShengZhong Investment Mangement Co ,Ltd — Series B
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series C
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series C
- Shanghai STVC Group (https://capitalatlas.ai/funds/shanghai-stvc-group) — Series C
- Xiamen C&D Group — Series C
- Lanchi Ventures (https://capitalatlas.ai/funds/lanchi-ventures) — Series C
- NRL Capital (https://capitalatlas.ai/funds/nrl-capital) — Series C
- True Light Capital (https://capitalatlas.ai/funds/true-light-capital) — Series C
- Tencent Investment — Series C